Project Grant R01DK142791
- This federal Project Grant award of $304,993 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Immunowork LLC, located in Monrovia, CA. The award supports a research project to quantify peripheral blood antigen-specific memory B cells as a new biomarker in patients with PLA2R-associated membranous nephropathy, a common form of nephrotic syndrome. The goal...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $343,650 to Rush University Medical Center to conduct research on Hodgkin's lymphoma-induced nephrotic syndrome. The research aims to investigate how cytokines and soluble proteins released by Hodgkin Reed-Sternberg cells trigger glomerular injury and albuminuria in mice with a...
- This $128,286 Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will support research into the mechanisms of renal lipotoxicity and its contribution to the development of chronic kidney disease (CKD). The principal investigator will investigate the protective role of the FAF2 gene knockout in mitigating palmitate-induced lipotoxicity in...
- This Project Grant award of $277,089, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to improve understanding of the genetic drivers of nephrotic syndrome (NS) in order to guide clinical management and develop targeted therapies. The research, conducted by The Children's Hospital Corporation (dba Boston Children's Hospital), will investigate the...
- This federal Project Grant award of $661,694, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to enhance the understanding of the role of the FANCD2 protein in kidney development, repair, and chronic kidney disease. The award supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital, to investigate FANCD2's...
- This federal Project Grant award of $305,786 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Cypress Biopharma, Inc. The grant supports research to develop a novel non-immunosuppressive therapy for childhood nephrotic syndrome (NS). The project aims to leverage the highly active metabolite of pioglitazone as a scaffold to design a drug that can...
- This Project Grant award of $830,500.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) supports research investigating the role of glycosphingolipids in kidney disease associated with diabetes and obesity. The key objectives are to: Test whether inhibiting glucosylceramide synthesis in podocytes, renal tubules, or the immune system can prevent progression of kidney disease in mouse...
- This $400,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to understand the earliest events in podocyte injury in collagen IV nephropathies. The goal is to investigate how processing of mutant collagen IV proteins injures podocytes at early stages, leading to chronic kidney disease and renal failure. The research uses...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $659,182 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Rhode Island Hospital, a division of Lifespan Corporation. The funding will support research to elucidate the role and mechanism of histone deacetylase 6 (HDAC6) in cisplatin-induced kidney injury, fibrosis, and chronic kidney disease, and to identify HDAC6 inhibition as a novel approach for...
- This federal Project Grant award of $193,984 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the interplay between inflammation, angiogenesis, myocardial perfusion, and myocardial function in patients with advanced chronic kidney disease (CKD). The project, conducted by Brigham & Women's Hospital Inc., aims to mechanistically explore cardiovascular health before and after kidney transplantation. Key objectives...
This Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to develop a novel kidney-draining lymph node-targeted nanotherapeutic for treating crescentic glomerulonephritis (CGN), a severe immune-mediated kidney condition. The $2,466,907 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, aims to investigate the role of the cytokine TNFSF14 (LIGHT) in regulating the pro-inflammatory properties of fibroblastic reticular cells, which play a key part in the adaptive immune response during CGN. The 4-year project period runs from September 1, 2025 to August 31, 2029 and seeks to address the lack of targeted treatments for CGN by leveraging the researchers' previous findings on the kidney lymph node as a central site for regulating the immune response in this condition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.5m | 8/29/25 |